NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE198701 Query DataSets for GSE198701
Status Public on Mar 16, 2022
Title Platinum-sensitive HGOC residual tumors share joint expression of CRYAB, CEACAM6, SOX2 genes with tumors that acquired resistance
Organism Homo sapiens
Experiment type Expression profiling by array
Summary Purpose: Most High-Grade Ovarian Carcinomas (HGOCs) are sensitive to carboplatin (CBP)-based chemotherapy but frequently recur within 24 months. Recurrent tumors remain frequently CBP-sensitive and acquire resistance after several CBP cycles. We developed Patient-Derived Xenografts (PDXs) that allow the study of these different stages of CBP-sensitive recurrence and acquisition of resistance.
Experimental Design: We generated PDX models from CBP-sensitive HGOC. PDXs were CBP- or mock-treated and tumors were sampled, after treatment and at recurrence. We also isolated models with acquired-resistance from CBP-sensitive PDXs upon repeated CBP treatment. Tumors were characterized transcriptome levels by Affymetrix microarrays.
Results: All PDX models reproduced treatment response seen in the patients. CBP-sensitive residual tumors contained non-proliferating tumor cells clusters embedded in a fibrotic mesh. This was absent in CBP-resistant tumors. Residual tumors had marked differences in gene expression when compared to naïve and recurrent tumors, indicating downregulation of cell cycle and proliferation and upregulation of interferon response and epithelial–mesenchymal transition. This gene expression pattern resembled that seen in embryonal diapause and ‘drug-tolerant persister’ states. Residual and acquired-resistance tumors share the overexpression of three genes – CEACAM6, CRYAB, and SOX2.
Conclusions: In HGOC PDX, CBP-sensitive recurrences arise from a small population of quiescent, drug-tolerant, residual cells embedded in a fibrotic mesh. These cells overexpress CEACAM6, CRYAB and SOX2, a signature also associated with acquired resistance and poor patient prognosis
 
Overall design design 1 : To analyze residual cells after treatment of 3 CBP-sensitive Patient-Derived Xenografts (PDX), using Affymetrix microarrays, for a total of 12 samples (2 mock-treated biological duplicates and 2 CBP-treated biological duplicates X 3 PDX models).
design 2: Patient-Derived Xenografts (PDX) were analyzed using Affymetrix microarrays,in naive(nai), after recurrence (regrowth=reg), or after acquired-resistance(resis) following several cycle of CBP treatments.
 
Contributor(s) du Manoir S, Theillet C, Sardet C
Citation missing Has this study been published? Please login to update or notify GEO.
Submission date Mar 15, 2022
Last update date Mar 18, 2022
Contact name stanislas P du manoir
E-mail(s) stanislas.dumanoir@inserm.fr
Organization name IRCM
Lab Genetic and phenotypic plasticity of cancer team
Street address 280 rue des apothicaires
City montpellier
ZIP/Postal code 34298
Country France
 
Platforms (1)
GPL13158 [HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate
Samples (20)
GSM5955378 PDX O1047, mock treated, rep1
GSM5955379 PDX O1047, mock treated, rep2
GSM5955380 PDX O1047, CBP treated, rep1
Relations
BioProject PRJNA816496

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE198701_RAW.tar 42.5 Mb (http)(custom) TAR (of CEL)
GSE198701_stanislas.dumanoirFinalTable.txt.gz 1.5 Mb (ftp)(http) TXT
Processed data included within Sample table
Processed data are available on Series record

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap